Please note that following on from information provided to NICE by the company in April 2023 , the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1221 |
Project Team
| Project lead | Michelle Adhémar |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 November 2024 | Discontinued. Please note that following on from information provided to NICE by the company in April 2023 , the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 04 April 2023 | For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 25 August 2022 | Suspended. The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of ibrutinib for untreated mantle cell lymphoma ID1221. The company that market ibrutinib have informed NICE that it will not provide an evidence submission for the evaluation. In light of this information NICE will not be progressing with the scoping exercise. Please accept our apologies for any inconvenience this may cause. |
| 02 August 2022 | Scoping commenced |
| 30 May 2018 | As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ibrutinib for untreated mantle cell lymphoma. Following an update from the company, the timelines for this appraisal are to be confirmed in order to align with latest regulatory expectations. Therefore, NICE will continue to monitor development and will update interested parties as and when the situation changes. |
| 26 June 2017 | In progress. Topic referred |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual